Sugi Predict

Sugi Predict / Compounds / SCHEMBL588761

SCHEMBL588761

SCHEMBL588761

Cc1cnc(Nc2cccc(CS(C)(=O)=O)c2)nc1Nc1ccc2c(C)n[nH]c2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKMYT1 Q99640 1/20 0.59
▸ JAK1 P23458 15/20 0.52
▸ JAK3 P52333 10/20 0.52
▸ JAK2 O60674 8/20 0.49
▸ SYK P43405 3/20 0.47
▸ EGFR P00533 3/20 0.47
▸ BTK Q06187 2/20 0.47
▸ ITK Q08881 2/20 0.46
▸ CDC7 O00311 1/20 0.46
▸ PLK4 O00444 1/20 0.46
▸ CHEK1 O14757 1/20 0.46
▸ AURKA O14965 1/20 0.46
▸ DCLK1 O15075 1/20 0.46
▸ PDPK1 O15530 1/20 0.46
▸ DAPK3 O43293 1/20 0.46
▸ ROCK2 O75116 1/20 0.46
▸ MAP4K4 O95819 1/20 0.46
▸ PAK4 O96013 1/20 0.46
▸ CHEK2 O96017 1/20 0.46
▸ ABL1 P00519 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL588573 0.89 NEK2 (0.47) PKMYT1JAK1JAK3JAK2SYK
SCHEMBL10151169 0.88 CCNT1 (0.49) PKMYT1CDK1LYNSRCCDK2
SCHEMBL588639 0.87 JAK1 (0.66) JAK1JAK3JAK2SYKEGFR
SCHEMBL589262 0.86 NEK2 (0.46) PKMYT1RETMETFLT1CDK2
Hydrochloric Acid SCHEMBL589256 0.85 NEK2 (0.46) PKMYT1RETMETFLT1CDK2
SCHEMBL588491 0.84 JAK3 (0.64) JAK1JAK3JAK2SYKEGFR
SCHEMBL4811690 0.82 PKMYT1 (0.67) PKMYT1JAK1JAK3JAK2SYK
SCHEMBL589265 0.79 SYK (0.48) JAK1JAK3SYKEGFRBTK
SCHEMBL31672441 0.78 KDR (0.46) PKMYT1CDK2KDR
SCHEMBL2877133 0.78 KDR (0.46) PKMYT1CDK2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2311825-B1 Pyrimidineamines as angiogenesis modulators NOVARTIS AG (CH) 2015-10-07 — — EP claimed
EP-2311825-A1 Pyrimidineamines as angiogenesis modulators GlaxoSmithKline LLC (US) 2011-04-20 — — EP claimed
US-7262203-B2 Pyrimidineamines as angiogenesis modulators SMITHKLINE BEECHAM CORPORATION (US) 2007-08-28 — — US claimed
US-20070015756-A1 Chemical compounds NOVARTIS AG (CH) 2007-01-18 — — US claimed
US-20040242578-A1 Pyrimidineamines as angiogenesis modulators NOVARTIS AG (CH) 2004-12-02 — — US claimed
EP-3789027-A1 BOSUTINIB, SUNITINIB, TIVOZANIB, IMATINIB, NILOTINIB, REBASTINIB OR BAFETINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2021-03-10 — — EP disclosed
US-20180000771-A1 AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2018-01-04 — — US disclosed
EP-3246046-A1 AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2017-11-22 — — EP disclosed
EP-2311825-B1 Pyrimidineamines as angiogenesis modulators NOVARTIS AG (CH) 2015-10-07 — — EP disclosed
US-20120277258-A1 Chemical Compounds LEO OSPREY LIMITED (JE) 2012-11-01 — — US disclosed
US-8114885-B2 Pazopanib hydrochloride and synthesis, chemical intermediates, and dosage forms thereof; anticancer; colon cancer, breast cancer GLAXOSMITHKLINE LLC (US) 2012-02-14 — — US disclosed
EP-2311825-A1 Pyrimidineamines as angiogenesis modulators GlaxoSmithKline LLC (US) 2011-04-20 — — EP disclosed
US-20100105712-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2010-04-29 — — US disclosed
EP-1343782-B1 PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS SMITHKLINE BEECHAM CORP (US) 2009-05-06 — — EP disclosed
US-20070292513-A1 CHEMICAL COMPOUNDS NOVARTIS AG (CH) 2007-12-20 — — US disclosed
US-20070270427-A1 CHEMICAL COMPOUNDS NOVARTIS AG (CH) 2007-11-22 — — US disclosed
US-7262203-B2 Pyrimidineamines as angiogenesis modulators SMITHKLINE BEECHAM CORPORATION (US) 2007-08-28 — — US disclosed
US-20070015756-A1 Chemical compounds NOVARTIS AG (CH) 2007-01-18 — — US disclosed
US-7105530-B2 inhibitors of vascular endothelial growth factor receptor-2 kinase; pazopanib and salts; for proliferative retinopathy; anticancer SMITHKLINE BEECHAM CORPORATION (US) 2006-09-12 — — US disclosed
US-20040242578-A1 Pyrimidineamines as angiogenesis modulators NOVARTIS AG (CH) 2004-12-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242578-A1 Pyrimidineamines as angiogenesis modulators TYMS, TYMP, DPYD PKMYT1 1205/4885JAK1 309/4885JAK3 267/4885
US-20070015756-A1 Chemical compounds KDR, FLT4, FLT1 PKMYT1 1367/4885JAK1 124/4885JAK3 136/4885
US-20100105712-A1 CHEMICAL COMPOUNDS KDR, FLT4, FLT1 PKMYT1 1367/4885JAK1 124/4885JAK3 136/4885
US-20180000771-A1 AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS WEE2, WEE1, ERBB2 PKMYT1 1386/4885JAK1 24/4885JAK3 9/4885
US-20120277258-A1 Chemical Compounds KDR, FLT4, FLT1 PKMYT1 1367/4885JAK1 124/4885JAK3 136/4885
US-20070270427-A1 CHEMICAL COMPOUNDS KDR, FLT4, FLT1 PKMYT1 1367/4885JAK1 124/4885JAK3 136/4885
US-20070292513-A1 CHEMICAL COMPOUNDS KDR, FLT4, FLT1 PKMYT1 1367/4885JAK1 124/4885JAK3 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.